We recently published a list of Jim Cramer Commented On These 6 Stocks Recently. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY)) stands against other stocks that Jim Cramer commented discussed recently.

We recently compiled a list of the 10 Stocks With At Least $10 Million In Insider Sales Recently. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks.

In its fourth quarter 2024 investor letter, Polen Focus Growth Strategy emphasized stocks such as Eli Lilly and Company (NYSE:LLY). Eli Lilly and Company (NYSE:LLY) is a pharmaceutical company ...

Pharmaceutical giant expects the move will create 3,000 high-skilled jobs and provide work for approximately 10,000 construction workers.

Eli Lilly and Company (NYSE: LLY) will participate in Leerink Partners Global Healthcare Conference on March 10, 2025. Lucas Montarce, Lilly executive vice president and chief financial officer ...

Institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its holdings in Eli Lilly and Company by 0.6% during the fourth quarter. Vanguard Group ...

Eli Lilly and Co. is in negotiations with several states and plans to announce the locations of four new manufacturing plants later this year.

It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. Let's figure out how Lilly could perform through the end of the decade, and decide whether it's still worth investing in the stock.

Eli Lilly partnered up with telehealth providers LifeMD and Teladoc Health to offer its lower cost, single-vial Zepbound (tirzepatide) to patients in the virtual c | The move could be a boon for telehealth weight loss programs,

A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture knockoff versions of Eli Lilly's tirzepatide while a lawsuit plays out. | A Texas court has rejected a request by compounders to extend their ability to manufacture knockoff versions of Eli Lilly's tirzepatide while a lawsuit plays out.

The partnership comes as telehealth companies grapple with restrictions on the sale of some compounded GLP-1s.